AbbVie's Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn's Disease

​​​​​​​The FDA's decision is based on positive results from two induction and one maintenance clinical study of AbbVie's Skyrizi for Crohn's disease.

Related Keywords

Thomas Hudson ,Abbvie Skyrizi ,Derick Gonzales ,Courtesy Of Abbvie Inc ,Abbvie Inc ,Drug Administration ,Simple Endoscopic Score ,Disease Activity Index ,Vie Chairman ,Chief Executive Rick Gonzales ,Resume ,Careers ,Bbvie 39s Skyrizi Becomes First Fda Approved Il 23 Inhibitor For Crohn Disease ,Iospace ,Advice ,